39 Clinical, Medical & Diagnostic Products Custom Monoclonal Antibody Reveals HER2+ Breast Cancer Target


AMSBIO has supplied a tailor-made monoclonal antibody (mAB) to TU Dortmund researchers in Germany. This mAB aims to decode EDI3’s role in breast cancer development, how it’s controlled by HER2 signalling, and its therapeutic potential.


HER2+ breast cancer, marked by excessive Human Epidermal Growth Factor Receptor 2 (HER2) expression, is an extremely aggressive cancer subtype. Despite advancements in HER2-targeted therapies, the persistence of treatment resistance, both acquired and inherent, necessitates exploration of alternative therapeutic targets.


Under the leadership of Dr Rosemarie Marchan, a group of researchers has undertaken an extensive study to investigate the clinical significance of EDI3, a glycerophosphodiesterase enzyme linked to choline metabolism, within HER2-positive breast cancer. They utilised the custom monoclonal antibody against EID3, provided by AMSBIO, in their research.


Dr Marchan commented: “We have tested many off-the-shelf antibodies over the years, with little to no success. We have also contracted companies to create a custom antibody for us, but again with limited success. Therefore, we are very thankful a few years ago that we were able to get a great antibody against EID3 from AMSBIO. Using this precious antibody our team has been able to demonstrate that inhibiting EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth.”


Read the full case study describing the work of Dr Marchan and her team in the Leibniz Research Centre for Working Environment and Human Factors (IfADo) at the TU Dortmund: ilmt.co/PL/JeQM


With a track record of providing products to numerous industrial and academic projects over the past two decades, AMSBIO has gained widespread recognition as a leading supplier of both ready- made and tailored antibodies. Their services encompass the creation of custom monoclonal antibodies tailored to your specific target antigen, delivering a well-informed and high-quality solution. More information online: ilmt.co/PL/dL1K


61146pr@reply-direct.com Revolutionising Tumour Screening with Lab-on-Chip Technology


Glasgow-based company, ScreenIn3D, highlights their distinctive lab-on-a-chip technology, which empowers cancer researchers to miniaturise their examination of biopsy tissue samples across an extensive array of modalities. This innovation also facilitates the evaluation of both individual and combined drug treatments on viable tissue samples.


By harnessing the latest advances in microfluidics and 3D cell culture, ScreenIn3D’s unique chip technology empowers researchers to conduct scores of 3D cancer screening experiments using as few as 1000 cells. Backed by investments from Gabriel Investments Ltd, Scottish Enterprise, and the University of Strathclyde’s Entrepreneurial Fund, ScreenIn3D is poised to enhance the platform’s capabilities for testing novel tumour indications and to scale up chip production. This expansion aims to extend the platform’s availability to pharmaceutical and biotech firms seeking to license the technology for internal utilisation. The integration of this ground-breaking technology into testing protocols holds the potential to revolutionise pharmaceutical companies’ capacity to rapidly assess drug effectiveness on patient-derived tumours. This advancement amplifies their initiatives by generating more physiologically relevant data, setting it apart from conventional biopsy approaches reliant on non-viable or deceased cells.


Dr Michele Zagnoni, Chief Executive Officer of ScreenIn3D, commented: “There are challenges with evaluating solid tumours, not just cancerous cells but those surrounding them and their interactions with immuno-cells. Tumour tissue is a precious resource, which is underutilised in drug development due to high cost and its limited quantity. Our technology offers a completely new way to test a vast number of combination therapies on patient-derived samples, offering drug developers increased opportunities of finding new treatments, quicker and with less failures.”


ScreenIn3D co-founder, Alex Sim, further continued: “Drug development is expensive. We have developed a technology platform which could accelerate the development of therapies on models that are representative of what happens in the body during disease. This bold approach will unlock remarkable advancements for precision oncology. For example, how to tailor an anticancer treatment to an individual patient, reduce animal tests and profoundly impact the way drugs can be developed for other diseases in the future.”


More information online: ilmt.co/PL/lZEj 61056pr@reply-direct.com New Chromosomal Microarray with Two-day Turnaround


Thermo Fisher Scientific has introduced a ground-breaking chromosomal microarray, the Applied Biosystems™ CytoScan™ HD Accel array, boasting an industry-leading two- day turnaround time. Designed to enhance productivity, efficiency, and profitability in cytogenetic research labs, it provides insights into chromosomal variants for a broad range of applications, including prenatal, postnatal, and oncology research.


In the face of growing demand and a shortage of trained lab professionals, labs are increasingly pressured to improve efficiency. The CytoScan HD Accel array can elevate assay productivity by up to 100% using existing equipment, reducing sample handling and preparation time. Remarkably, it requires as little as 100 ng of input DNA, significantly less than other commercially available chromosomal microarrays.


Kevin Lowitz, Vice President and General Manager of Microarray Genetic Solutions at Thermo Fisher Scientific, highlighted the array’s capacity to save labs weeks or even months annually. With its scalability and ability to deliver reliable, reproducible results swiftly, microarray technology emerges as a cost-effective choice for cytogenetic research.


The CytoScan HD Accel array offers improved data quality through an expanded reference model, accommodating various sample types, from buccal swabs to blood. Thermo Fisher continues to support customers in advancing cytogenetic research, with updates to its instrumentation and services, including enhanced data analysis software and instrument upgrades for array processing.


More information online: ilmt.co/PL/eb3B 61193pr@reply-direct.com Monoclonal Antibodies to Avian Infl uenza Viruses


The CDC reports that the H5N1 Bird Flu has been detected in several species of wild birds as well as domestic poultry flocks. Sporadic infections with this virus have also been detected in mammals (fox, raccoon, skunks, mountain lions). One US case has been reported following exposure to infected birds, but no person-to-person transmission has occurred.


ViroStat’s monoclonal antibodies target the highly conserved nucleoprotein of the Influenza A virus. Thus these monoclonal antibody pairs detect many Flu A isolates found in human, avian, swine and equine sources. These include viruses of H1-H14 types and N1-N9 types. Immunoassays utilising these antibody pairs are useful for detecting Flu A in humans as well as for surveillance of circulation in other animal species.


More information online: ilmt.co/PL/jXK8 61045pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64